8640 Stock Overview
Operates as a clinical-stage biopharmaceutical company that uses biomarker technology to identify enzyme targets associated with serious common diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Lixte Biotechnology Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.63 |
| 52 Week High | US$15.00 |
| 52 Week Low | US$4.12 |
| Beta | -0.44 |
| 11 Month Change | 0% |
| 3 Month Change | -89.75% |
| 1 Year Change | -90.74% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8640 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 4.0% | 0.09% |
| 1Y | -90.7% | -19.2% | 3.1% |
Return vs Industry: 8640 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: 8640 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 8640 volatility | |
|---|---|
| 8640 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 8640's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 8640's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 4 | John Kovach | lixte.com |
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher’s disease, as well as cancer and neurodegenerative diseases.
Lixte Biotechnology Holdings, Inc. Fundamentals Summary
| 8640 fundamental statistics | |
|---|---|
| Market cap | €5.24m |
| Earnings (TTM) | -€5.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs 8640 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8640 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$6.15m |
| Earnings | -US$6.15m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.73 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 8640 perform over the long term?
See historical performance and comparison